...Paola Fulghieri; Lucia Anna Stivala; Virginie Sottile Cancer has been traditionally viewed as a disease characterised by excessive and uncontrolled proliferation, leading to the development of cytotoxic therapies against highly proliferating malignant cells. However, tumours frequently relapse due...

... the pharmacokinetics and pharmacodynamics are dissociated. The three murine models to be discussed each show BiP induced long-term therapeutic protection and therefore has potential for long-lasting drug-free therapy in rheumatoid arthritis (RA). During the pre-clinical investigations for rhuBiP, we used three...

... that make the ATX–LPA signalling axis an emerging target for cancer therapy. We examined the effect of silencing ATX expression in the B16 melanoma metastasis model syngeneic to the C57BL/6 mouse strain. ATX expression was knocked down using a lentivirally delivered shRNA (small hairpin RNA) construct...

...Chern Ein Oon; Adrian L. Harris Notch signalling is a key pathway controlling angiogenesis in normal tissues and tumours. This has become a major focus of development of anticancer therapy, but to develop this appropriately, we need further understanding of the mechanisms of regulation of Dll4...

...Qizhi Huang; Laura J. Hardie Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy. Routes to the identification of biomarkers have been recognized by known molecular...

... with the involvement of metal ions. Chelation therapy could provide a valuable therapeutic approach to such disease states, since metals, particularly iron, are realistic pharmacological targets for the rational design of new therapeutic agents. 1 To whom correspondence should be addressed (email robert.hider...

...) small hairpin RNA (shRNA) target validation therapy Disorders of the central nervous system are among the most complex, poorly understood, and debilitating diseases. The burgeoning advances in functional genomic technologies have led to the identification of a vast number of novel genes...

.... 1 To whom correspondence should be addressed (email dominic.walsh@ucd.ie ). 5 10 2006 © 2007 The Biochemical Society 2007 Alzheimer's disease β-amyloid-cleaving enzyme (BACE) amyloid precursor protein (APP) amyloid precursor-like protein (APLP) γ-secretase therapy...

... will play an even more vital role in the generation of future therapies. The genetic modification of animal models is becoming an increasingly common approach to study drug efficacy and safety both in vivo and ex vivo [ 10 ]. The generation of transgenic and knockout mice has benefited from...

...H. Valdimarsson Our first experience of mannan-binding lectin (MBL)-replacement therapy was with a patient experiencing recurrent erythema multiforme associated with reactivation of herpes simplex virus; his erythematous eruptions could be controlled with infusions of fresh frozen plasma containing...

... the natural history of (e.g. rheumatoid arthritis, cystic fibrosis), a disease. MBL (plasma-derived or recombinant) therapy has yet to be shown to be safe and effective. Potentially it may be useful in MBL-deficient patients to reduce susceptibility to, or enhance recovery from, bacterial infection...

... Biochemical Society 2003 complement innate immunity mannan-binding lectin (MBL) recombinant mannan-binding lectin therapy Abbreviations used: MBL, mannan-binding lectin; pMBL, plasma-derived MBL; rMBL, recombinant MBL; MASP, MBL-associated serine protease; MALDI-MS, matrix-assisted laser...

... therapy in disease. Here we will review the development of anticomplement therapeutics from the first generation agents, which are unmodified recombinant forms of natural regulators, to recent strategies for making better drugs. We will describe strategies for targeting the anticomplement activity...